SBHMY
Price
$18.65
Change
+$1.15 (+6.57%)
Updated
Jul 28 closing price
Capitalization
16.62B
VIVS
Price
$1.75
Change
-$0.00 (-0.00%)
Updated
Aug 8, 10:54 AM (EDT)
Capitalization
4.54M
Interact to see
Advertisement

SBHMY vs VIVS

Header iconSBHMY vs VIVS Comparison
Open Charts SBHMY vs VIVSBanner chart's image
Sino Biopharmaceutical
Price$18.65
Change+$1.15 (+6.57%)
Volume$1.03K
Capitalization16.62B
VivoSim Lab
Price$1.75
Change-$0.00 (-0.00%)
Volume$100
Capitalization4.54M
SBHMY vs VIVS Comparison Chart in %
Loading...
SBHMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VIVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SBHMY vs. VIVS commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SBHMY is a Buy and VIVS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (SBHMY: $18.65 vs. VIVS: $1.75)
Brand notoriety: SBHMY and VIVS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SBHMY: 299% vs. VIVS: 69%
Market capitalization -- SBHMY: $16.62B vs. VIVS: $4.54M
SBHMY [@Biotechnology] is valued at $16.62B. VIVS’s [@Biotechnology] market capitalization is $4.54M. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SBHMY’s FA Score shows that 3 FA rating(s) are green whileVIVS’s FA Score has 1 green FA rating(s).

  • SBHMY’s FA Score: 3 green, 2 red.
  • VIVS’s FA Score: 1 green, 4 red.
According to our system of comparison, SBHMY is a better buy in the long-term than VIVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SBHMY’s TA Score shows that 1 TA indicator(s) are bullish while VIVS’s TA Score has 4 bullish TA indicator(s).

  • SBHMY’s TA Score: 1 bullish, 3 bearish.
  • VIVS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, SBHMY is a better buy in the short-term than VIVS.

Price Growth

SBHMY (@Biotechnology) experienced а 0.00% price change this week, while VIVS (@Biotechnology) price change was -6.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +8.39%, and the average quarterly price growth was +12.02%.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SBHMY($16.6B) has a higher market cap than VIVS($4.54M). VIVS YTD gains are higher at: 279.865 vs. SBHMY (128.675). SBHMY has higher annual earnings (EBITDA): 6.89B vs. VIVS (-2.21M). SBHMY has higher revenues than VIVS: SBHMY (28.9B) vs VIVS (144K).
SBHMYVIVSSBHMY / VIVS
Capitalization16.6B4.54M365,478%
EBITDA6.89B-2.21M-311,946%
Gain YTD128.675279.86546%
P/E Ratio63.82N/A-
Revenue28.9B144K20,069,444%
Total CashN/A11.3M-
Total DebtN/A942K-
FUNDAMENTALS RATINGS
SBHMY vs VIVS: Fundamental Ratings
SBHMY
VIVS
OUTLOOK RATING
1..100
3676
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
17
Undervalued
PROFIT vs RISK RATING
1..100
10093
SMR RATING
1..100
2797
PRICE GROWTH RATING
1..100
3535
P/E GROWTH RATING
1..100
7100
SEASONALITY SCORE
1..100
n/a8

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SBHMY's Valuation (3) in the null industry is in the same range as VIVS (17) in the Biotechnology industry. This means that SBHMY’s stock grew similarly to VIVS’s over the last 12 months.

VIVS's Profit vs Risk Rating (93) in the Biotechnology industry is in the same range as SBHMY (100) in the null industry. This means that VIVS’s stock grew similarly to SBHMY’s over the last 12 months.

SBHMY's SMR Rating (27) in the null industry is significantly better than the same rating for VIVS (97) in the Biotechnology industry. This means that SBHMY’s stock grew significantly faster than VIVS’s over the last 12 months.

SBHMY's Price Growth Rating (35) in the null industry is in the same range as VIVS (35) in the Biotechnology industry. This means that SBHMY’s stock grew similarly to VIVS’s over the last 12 months.

SBHMY's P/E Growth Rating (7) in the null industry is significantly better than the same rating for VIVS (100) in the Biotechnology industry. This means that SBHMY’s stock grew significantly faster than VIVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SBHMYVIVS
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
38%
Bullish Trend 1 day ago
89%
Momentum
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
33%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
33%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
36%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
N/A
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
N/A
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
50%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
39%
Bullish Trend 1 day ago
51%
View a ticker or compare two or three
Interact to see
Advertisement
SBHMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VIVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FLBR17.670.33
+1.88%
Franklin FTSE Brazil ETF
CHI10.350.09
+0.88%
Calamos Convertible Opportunities and Income Fund
HYRM23.36N/A
N/A
Xtrackers Risk Managed USD HY Strat ETF
LQD109.76-0.11
-0.10%
iShares iBoxx $ Invmt Grade Corp Bd ETF
STXM26.74-0.07
-0.26%
Strive Mid-Cap ETF

SBHMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SBHMY has been loosely correlated with TENX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if SBHMY jumps, then TENX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SBHMY
1D Price
Change %
SBHMY100%
N/A
TENX - SBHMY
42%
Loosely correlated
-2.13%
SYBX - SBHMY
34%
Loosely correlated
-1.38%
BTAI - SBHMY
32%
Poorly correlated
+2.71%
CLRPF - SBHMY
24%
Poorly correlated
-10.09%
VIVS - SBHMY
20%
Poorly correlated
-2.40%
More

VIVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VIVS has been loosely correlated with LVTX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if VIVS jumps, then LVTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VIVS
1D Price
Change %
VIVS100%
-2.40%
LVTX - VIVS
42%
Loosely correlated
N/A
GLTO - VIVS
38%
Loosely correlated
-4.12%
ORMP - VIVS
37%
Loosely correlated
-0.24%
ACET - VIVS
27%
Poorly correlated
-1.97%
KRRO - VIVS
26%
Poorly correlated
+1.15%
More